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Abstract
Effect of Ultrasound Pressure on the Distribution of Bovine Serum Albumin Delivered by
Focused Ultrasound-Blood Brain Barrier Opening in Cleared Mouse Brains
By
Yajie Liu
Master of Science in Biomedical Engineering
Washington University in St. Louis, 2021
Research Advisor: Professor Hong Chen

Most common diagnosis and therapeutic methods have low effectiveness when used on
brain diseases. The key obstacle is that the blood-brain barrier (BBB) prevents most drugs from
entering the brain. Some strategies have been developed to improve the efficiency of drug
delivery crossing BBB. Among all these strategies, focused ultrasound-mediated BBB opening
(FUS-BBB Opening) stands out since it is noninvasive and can be located to the target area.
Detailed studies are required on the distribution of drugs delivered by FUS-BBB opening and the
effects of FUS parameters on the distribution. This thesis proposes a pipeline involving tissue
clearing and lightsheet microscopy to study the distribution of BSA relative to vessels in mouse
brains treated with FUS and the effect of ultrasound pressure on the delivery pattern.
As mentioned before, slices (1 mm thick) from mouse brains treated with FUS were cleared
until their transparency meets the requirement of large-volume three-dimensional (3D) imaging.
Blood vessels and BSA clusters in the 3D images obtained from lightsheet microscopy
were segmented and the distance of every cluster from the nearest vessel was collected in the
distance map.
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Comparing the distance maps of different pressures, it is indicated that FUS with the
pressure

of

0.4

MPa

significantly

increases

the

amount

of

BSA clusters

in

brains, especially those distributed closer to the outer surface of vessels. BSA delivered by 0.2
MPa FUS and 0.4 MPa FUS has different distribution patterns relative to vessels. At the same time,
this thesis discussed the feasibility of this pipeline to study FUS-BBB opening-induced drug
delivery.
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Chapter 1: Introduction
Background
The brain is one of the most important organs of humans. Brain diseases, like central
nervous

system

(CNS)

diseases

and

brain cancers, are

troubling

many

patients. In consequence, research about the physiological mechanism of the brain and the
treatment

of

brain

diseases

has

always

attracted

attention.

However,

due

to the existence of the blood-brain barrier (BBB), drugs for brain diseases only have poor
effects.(Dong, 2018) The advantages of FUS-BBB opening as noninvasive and localized
have been validated for the delivery of therapeutic and imaging agents. The distribution of drugs
is important to a drug delivery method since it not only plays a key role in clinical safety and
efficiency but also helps us to understand the physiological process during the delivery. Pressure
amplitude is a main parameter of FUS and has been proved to affect drug delivery crossing BBB.
However, studies on the 3D distribution of drugs relative to neuron vascular under different
pressures remain blank.
Tissue clearing has been used to visualize the biodistribution of delivered materials in brain
tissue as a pre-imaging processing technique because of its advantage in the visualization of
intact tissue. Tissue clearing matches the refractive indices of different tissue layers and improves
the transmission of light so that it can increase the imaging depth by removal of the light scattering
and adsorbing substance.(Arms et al., 2020) On the other hand, it can still provide us
with spatial information since it preserves the main structure constituted by proteins. Validated
methods can make large samples transparent enough so that the imaging extent is only limited by
the working distance of objective lenses. The appearance of tissue clearing techniques helps us to
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achieve subcellular 3D imaging without deleterious sectioning on tissue and sophisticated data
reconstruction so that we avoid mechanical distortion as much as possible.
Drug Delivery Induced by FUS-BBB Opening
For a

long time,

how

to

cross

(BBB) has always been

the main

obstacle

to applying many diagnosis and therapeutic methods to brain diseases. Anatomically speaking,
BBB is a continuous layer of endothelial cells (ECs) on cerebral vascular. These ECs bound to
each other with tight junctions (TJs) and have extremely low rates of transcytosis compared with
peripheral ECs, so that restricts the paracellular flux and vesicle-mediated transcellular movement
of solutes.(Banks, 2008) ECs and their unique property to limit substance exchange between the
vascular system and central nervous system (CNS) together constitute the physiological BBB. In
the healthy brain, BBB is important to maintain the homeostasis of the CNS and protect it from
toxins and pathogens. However, BBB also prevents most therapeutic materials and imaging agents
circulating in the vasculature from arriving at the brain parenchyma, which reduces the efficiency
of drug delivery and correspondingly increases the systematic toxicity. Some strategies have been
developed to circumvent the BBB. However, intra-cerebral injection, use of implants or
convection-enhanced delivery are invasive and raise significant safety concerns. Modifying
drugs to take advantage the native BBB transport or transcytosis system requires excessive costs of
designing new drugs.(Gabathuler, 2010) Other strategies involving viral vectors, non-viral
nanoparticles and brain permeability enhancers have been indicated in recent publications that they
may not have enough therapeutic effects at a reasonable dosage of drugs.(Dong, 2018)
Focused ultrasound (FUS) combined with microbubbles (MBs) are discovered to be able
to disrupt the integrity of BBB without apparent neuronal injury. Compared with other strategies,
FUS-BBB opening is noninvasive and can be localized to the target area. As the research
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developed, the successful delivery by FUS-BBB opening has been verified for a wide range of
therapeutic

and

imaging

drugs,

such

as

radiolabeled

nanoclusters, liposomally-

encapsulated drugs and antibodies.
MBs are small-sized (1-5 µm) gas-filled vesicles stabilized by phospholipids, proteins or
polymers.(Dasgupta et al., 2016) Ultrasound is most well-known for its application
on clinical noninvasive real-time imaging. With ultrasound, MBs in the neuronal vascular may
contract, expand or burst, which will trigger a series of biophysical effects. The main consequence
of these effects will be the transient opening of ECs and the TJs between ECs leading to the
increase of microvascular permeability, thus improving the drug delivery across the BBB. In
addition, soft- and hardware techniques on focused ultrasound can limit the BBB opening within
small areas, improving the targeting of drug delivery and reducing the risk to the whole brain.
The pressure amplitude of FUS is an important parameter to BBB opening. Increasing the
pressure amplitude will increase the BBB permeability. With the same frequency, repetition
frequency and total exposure time, higher pressure intend to cause the BBB opening
at a larger area and the signal enhancement caused by the increase in the average delivery volume
of the magnetic resonance imaging (MRI) contrast agent per unit area.(Chopra et al., 2010)
The increase in pressure also tends to enlarge the BBB opening size, defined by the size of the
largest molecule that can cross the BBB.(Chen & Konofagou, 2014) However, excessive pressure
will cause tissue damage such as hemorrhage, necrotic and neuronal injury.(Chopra et al., 2010)
Tissue Clearing
The main principle of tissue clearing is the substitution of water in samples with
the solutions that have higher RI, which is closer to the tissue. In this procedure, the key problem
is how to prompt the material exchange between in- and outside tissue. Among all developed
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methods, some methods rely on chemical solvents and passive diffuse (passive and active
CLARITY, SWITCH). Most tissue clearing methods can be divided into two groups based on the
characteristic of the solvents they use: organic solvent (EtOH, THF)–based clearing methods
(3DISCO, iDISCO) and hydrophilic reagent (urea, D-sorbitol, fructose)–based clearing methods
(ScaleS, AbScale, CUBIC, FRUIT, UbasM, SeeDB). Although some organic solvent and amino
alcohol already can solubilize lipids, some methods also add detergent (SDS, Triton X-100) into
their recipe to improve the ability of lipid removal, therefore increase the transmission of light,
such as CLARITY, SWITCH, AbScale and CUBIC. Active CLARITY involves electrophoresis
to accelerate the penetration of detergent into tissue. Besides, although all methods require the
tissue to be fixed before clearing, the tissue-hydrogel crosslinking with acrylamide
in CLARITY provides more opportunity to retain protein and nanoparticles.
All these tissue clearing methods have their advantages as well as shortages. The
characteristics of several typical methods are shown below (Table 1)
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Table 1
Comparison of Tissue Clearing Methods
Method and
reference

Mechanism
of clearing

Procedure
time

Tissue
integrity

Preservation of
fluorescence

3DISCO(THF/T
BE)(Ertürk et al.,
2012)

Dehydration
with THF, RI
homogenizati
on with TBE

1 day for the
whole mouse
brain

0.8-fold
shrinkage

Better for CFP,
GFP, RFP, mCh
erry than YFP,
TBE degrades
fluorescent
signal over
time

ScaleS(Hama et
al., 2015)

RI
homogenizati
on via
molecule flux
by sorbitol
and urea
Lipid
removal by
detergent, RI
homogenizati
on by

4 days for the
whole mouse
brain

No
significant
size chang
es

4 days for
1mm thick
mouse brain
slice

Undergoes
expansion
during
clearing,
shrinks

AbScale(Hama et
al., 2015)(Hama
et al., 2011)

IHC
compati
bility
Yes

Nanoparticle
retention

Tissue
validated

polystyrenebased nanoparticles
(~500
nm) degrade ~150fold, insignificant
decrease for
melamine resinbased (~500 nm)
nanoparticles,
quantum dots (~20
nm) remain enough
signal-tobackground ratio(Y
ang et al., 2019)

mouse brain,
lung, spleen,
lymph nodes,
mammary gla
nds and
tumor
tissues,
human brain,

Good.

No

Polymeric
Mouse brain
nanoparticles(Ishiza and human
wa et al., 2020)
brain, mouse
liver

Good
for mCherry,
limited for
EGFP, GFPlike proteins.

Yes

Unknown

Mouse brain
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CLARITY
(active)(Flynn et
al., 2015)

CLARITY
(passive)(Sindhw
ani et al., 2017)

SeeDB

glycerol,
molecule flux
by sorbitol
and urea
Tissuehydrogel
crosslinking
with PFA and
acrylamide,
Lipid
removal with
SDS, RI
homogenizati
on with
glycerol,
molecule flux
by
electrophoresi
s
Tissuehydrogel
crosslinking
with PFA and
acrylamide,
Lipid
removal with
SDS, RI
homogenizati
on with
glycerol
RI
homogenizati
on via

~6 days for
whole mouse
brain

back after
RI
homogeni
zation
Undergoes
expansion
during
clearing,
shrinks
back after
RI
homogeni
zation

Signal
undergoes some
quenching
Good

Yes

After 4 days. ~70%
retention for 6 nm
PEGylated quantum
dots, ~84%
retention for 50 nm
Au-PEG

~21days for t
he whole
mouse brain

Undergoes Good
expansion
during
clearing,
shrinks
back after
RI
homogeni
zation

Yes

PEGylated quantum Rodent brain,
dots undergo 12%
spinal cord,
loss after 6 days
intestine,
kidney, lung,
liver, and
pancreas;
human brain;
and
zebrafish

4 days for the
whole mouse
brain

No
significant
size

Yes

unknown

Good for many
types of
fluorescent

Mouse brain,
spinal cord,
spleen,
pancreas,
intestine,
kidney, lung,
testis, and
muscle

Mouse brain,
olfactory
bulb.
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molecule flux
with aqueous
fructose
solutions

CUBIC(Susaki et
al., 2014)

Decolorize
the blood via
eluting heme
by amino
alcohol(Taina
ka et al.,
2014), lipids
removal
by amino
alcohol and
detergent, RI
homogenizati
on with
glycerol
and DMSO,
molecule
influx by
urea

10~14 days
for the whole
brain

change
and
morpholo
gical
deformati
ons
during the
whole
procedure
Undergoes
~1.35-fold
expansion
during
clearing,
shrinks
back after
RI
homogeni
zation

dyes, including
fluorescent
proteins and
lipophilic
neuronal
tracers

Good for
YES
EGFP,
EYFP, mCherry
and mKate2

axane-encapsulated
polymeric
nanoparticles remai
ned enough signalto-background
ratio in mouse
lung(Cuccarese et
al., 2017)

Whole
organ of the
mouse,
tumor
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Considering this study can be extended to observe the colocalization of BSA and neuron
cells, the IHC compatibility, fluorescence preservation ability and nanoparticle preservation ability
of these methods are mainly cared about. After carefully screening and balancing, we
pick AbScale as our protocol. As shown in the table, AbScale is compatible with
immunohistochemistry and can preserve most fluorescence by the end of tissue clearing. In the
protocol of AbScale, reagent-1 (ScaleS0) can solubilize cholesterol of biological membrane with
Methyl-β-cyclodextrin and γ-cyclodextrin and loosen collagen structure with N-acetyl-Lhydroxyproline. After the incubation in ScaleS0, the fixed tissue becomes loose enough to
exchange materials with the following reagents. Reagent-2 (ScaleA2) involves high concentration
urea to prompt the molecule influx, Triton X-100 to extract lipids. Reagent-3 (ScaleB4) has a 2fold higher concentration of urea to clear the tissue quickly. Reagent-4 (ScaleS4) contains glycerol
and DMSO for high RI (1.439). The molecule influx by urea and osmotically balanced molecule
flux by D-sorbitol in ScaleS4 accelerate the penetration of the solution.
So far there is a lack of reference on the loss of nanoparticles after clearing by AbScale.
However, bovine serum albumin (BSA) as a kind of protein can be linked to the crosslinking
formed by close endogenous proteins in the tissue through amino acids during fixation and postfixation. This process greatly improves the probability of the retention of delivered BSA after
tissue clearing, thus providing our study with more accurate information. In addition, BSA is a
competitive carrier of drugs, especially nanoparticle delivery drugs, so that involved in the therapy
of many kinds of cancers.(Elzoghby et al., 2012) BSA is serum albumin derived from cows and
has 583 amino acid residues. The molecule weight of BSA is 69323 Da. The dimension of a single
BSA particle is 140 × 40 × 40 Å. BSA is rich in nature and easy to be purified. It also has the
advantages of biodegradability, nontoxicity, safe degradation products after metabolized in vivo
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and non-immunogenicity. Last but not least, BSA nanoparticles can be prepared by
simple coacervation.(Galisteo-González & Molina-Bolívar, 2014) Therefore, BSA is a good drug
model for our study.
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Chapter 2: Materials and Methods
Animals
Animal protocols used in this study were reviewed and approved by the Institutional
Animal Care and Use Committee in accordance with the National Institutes of Health guidelines
for animal research (approval no. 20180186; date of approval: 12 August 2019). Cr. NIH Swiss
mice (6–8 weeks, ~25 g body weight, female) were ordered from Charles River Laboratory
(Wilmington, MA, USA). The animals were housed in a room maintained at 22 °C and 55%
relative humidity, with a 12-h/12-h light/dark cycle and access to standard laboratory chow and
water.
Drug Model
Albumin from Bovine Serum conjugated with Alexa FluorTM 647 (BSA-AF647)
was purchased from Thermo Fisher Scientific (Wilmington, DE, USA) and dissolved to 1.3
mg/mL with 1x Phosphate Buffered Saline (PBS) when in use.
FUS-BBB Opening Setup
The FUS-BBB opening treatment was finished with an in-house mini transducer.
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Workflow

Figure 2.1 Workflow and timeline.
(a) Workflow. (b) Timeline.
Experimental Procedure
BSA-AF647 Delivery via FUS-BBB Opening
6 mouses were anesthetized with a continuous flow of 2% isoflurane mixed with
oxygen. Then BSA-AF647 (4.29 µg/kg) and microbubbles (5 x 108/kg) were injected into the
mouse via tail vein. Treat the mouses with FUS setup on one side with different pressure (3 for 0.2
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MPa and 3 for 0.4 MPa). The frequency of the FUS transducer is 1.5 MHz After 15 mins, inject
Lycopersicon Esculentum

(Tomato)

Lectin

conjugated

with DyLight 488

(Thermo

Fisher Scientific, Wilmington, DE, USA) into the mouse via tail vein, followed by perfusion
immediately.
Transcardial Perfusion Fixation and Post-fixation
The transcardial perfusion was completed by a perfusion pump with a speed of 5.5 mL/min.
First, the blood was removed by 60 mL perfusion solution containing 1x PBS, 10 U/mL heparin
and 0.5% w/v sodium nitrite (Sigma Aldrich, St. Louis, MO, USA). Then the tissue was fixed
by perfusion with 50 mL fixation solution containing 1x PBS and 4% w/v paraformaldehyde (PFA)
(Sigma Aldrich, St. Louis, MO, USA). After being harvested from the mouse, the mouse brain was
incubated in 4% PFA/PBS at 4 °C for 10 hours.
AbScale Clearing
The fixed brains were sectioned as 1 mm thick slices. Before clearing, samples were
imaged by Pearl Trilogy Small Animal Imager to record the BSA delivery results. 2 slices
with a strong signal were selected to be cleared for each mouse.
In this protocol, ScaleS0 solution is made by mixing 1x PBS, 20% w/v D-sorbitol (Sigma
Aldrich, St. Louis, MO, USA), 1 mM Methyl-β-cyclodextrin (Sigma Aldrich, St. Louis, MO,
USA), 1 mM γ-cyclodextrin (TCI Chemicals, Tokyo, Japan), N-acetyl-L-hydroxyproline
(Oakwood Chemical, West Columbia, SC, USA), and 3% v/v Dimethyl sulfoxide (DMSO) and
adjusting the pH to 7.2 with NaOH and HCl. ScaleA2 solution contains dd water, 10% w/v
glycerol, 4 M urea and 0.1% Triton X-100. ScaleB4 solution is 8 M aqueous urea in dd water.
ScaleS4 solution contains dd water, 40% w/v D-sorbitol, 10% w/v glycerol, 4 M urea, 15% DMSO
and 0.1% Triton X-100.
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Selected slices were first incubated in ScaleS0 solution for 12 hours to permeabilize
the samples. Then the incubation solution was changed to ScaleA2 for 36 hours, followed by
ScaleB4 for 24 hours and changed back to ScaleA2 for another 12 hours. All incubation was
at 37 °C with shaking. The samples were washed with 1x PBS at 4 °C for 6 hours. Finally,
the samples

were

moved to

hours before imaging (Figure 2.2).

ScaleS4 solution

and

incubated

at

37 °C

for

12

14
Figure 2.2 Tissue opacity throughout the clearing process.
Light-sheet Imaging
After tissue clearing, samples were imaged with Pearl Trilogy Small Animal Imager to
record the BSA delivery results again. One pair of regions of interest (ROIs) was selected from
the slice with a stronger signal for each brain to be imaged with the lightsheet microscopy. Each
pair of ROIs contains one region on the ipsilateral side with the strongest signal and one symmetry
region on the contralateral side.
3D

imaging

of

clearing

samples containing BSA-AF647

was

done

using the

Zeiss Lightsheet 7 planar illumination microscope equipped with a 20X objective lens (NA=1,
RI=1.46).
The selected sample for each brain was taped to a sample holder by Loctite Super Glue and
incubated in the chamber full of ScaleS4 solution. The z step size was 0.57 um. The size of
each ROI was 450 × 450 × ~1500 µm (x, y, z). Raw images were collected from the ROI on the
ipsilateral sides followed by the ROI on the contralateral sides.
Image Analysis
BSA Cluster and Vessel Segmentation
Bitplane Imaris was used to analyze the raw images from lightsheet microscopy. Images
were cropped to the size of 450 x 450 x 500 um. For each pair of images, the contralateral one was
processed first. Surface, the built-in program in Imaris was used to segment vessels. According to
the image of the lectin channel, vessels are segmented as intact as possible by adjusting the
threshold. Then Spots function was used to detect BSA clusters. The threshold about mean
intensity in the BSA channel was adjusted until there were no clusters in the space far from vessels.
The assumption that BSA cannot transport cross BBB at all without FUS treatment was applied
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here. Vessels on the ipsilateral side were segmented independently while BSA clusters were
detected by the same threshold as the contralateral side processed previously.
Shortest Distance Map
The shortest distance (Figure 2.3) from BSA clusters to vessel was automatically
calculated by Imaris. The data was exported as Excel files and imported into GraphPad Prism 9
for later analysis and statistical plotting.

Figure 2.3 Definition of shortest distance from a BSA cluster to vessels.
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Chapter 3: Results
Effect of Tissue Clearing on FUS-delivered BSA

Figure 3.1 Fluorescence intensity in 2D images before and after tissue clearing, quantified by
Pearl Trilogy Small Animal Imager and MATLAB code.
The mean fluorescence intensity of the BSA channel on samples treated 0.2 MPa FUS
(Figure 3.1) has reduced 35.4% after clearing compared with before clearing. This ratio for 0.4
MPa samples is 41.0%.
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Quantification of BSA Clusters in 3D Images

Figure 3.2 Representative 3D images of lectin-stained blood vessels and BSA in cleared brain
slices.
(a) Representative 3D images of the ROI on the contralateral side. The top figure is a top view and
the bottom one is the side view. (b) BSA delivery result on the representative sample.
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(c) Representative 3D images of the ROI on the ipsilateral side. Insets, 100 µm. The pressure of
FUS used to treat this sample is 0.2 MPa.
Cleared mouse slices were imaged by an ORCA-Flash4.0 V3 Digital CMOS camera to
show the BSA distribution on the whole slice (Figure 3.2 b). Each pair of ROI includes one area
on the ipsilateral side which has apparent BSA retention and an area symmetrical to it. The red
box in Figure 3.2b describes the approximate location of the ROI. With the lightsheet microscope,
we obtained one pair of 3D images with a cross-section of 450 × 450 µm and a depth
of approximately 1.5 mm from the ipsilateral side (Figure 3.2 c) and the contralateral side (Figure
3.2 a). The transparency of 1 mm-thick brain slices cleared with AbScale is enough for large
volume 3D imaging. Under the same display setting, the BSA channel has apparently higher signal
intensity on the ipsilateral side than the contralateral side. However, there is a lack of obvious
difference of lectin between both sides. This indicates that BSA accumulated on the side treated
with FUS within 15 minutes after the injection of BSA and the treatment of FUS. Since the size of
the BSA single particle is much smaller than the resolution of the light sheet microscopy with
20× objective (lateral resolution: 1~2 µm), it is only able to distinguish clusters formed by
BSA in these images.
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Figure 3.3 BSA cluster and blood vessel segmentation in representative 3D images.
(a) Raw images and processed images with BSA cluster and blood vessel segmentation from the
contralateral side. Raw images are in the first column. Yellow spots in the second column represent
segmented BSA clusters. Green surfaces represent segmented blood vessels. (b) Raw images and
processed images with BSA cluster and blood vessel segmentation from the ipsilateral side. Raw
images are in the second column. Size of all 3D images, 450 x 450 x 500 um. The pressure of FUS
used to treat this sample is 0.2 MPa.
Compared to the raw image in Figure 3.3, the green surface is consistent with the
distribution

of

blood

vessels, showing that

the

vessel

segmentation

function can identify intact blood vessels stained with lectin and reflect their shape and spatial
distribution. However, vessel segmentation faces difficulties in some areas where the fluorescence
intensity is extremely low (the area indicated by the arrow in Figure 3.3a). Yellow spots are more
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distributed on the ipsilateral side, which is consistent with what we observed in the raw image.
Spots are denser where the fluorescence intensity of the BSA channel is stronger.
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Figure 3.4 BSA cluster and blood vessel segmentation in representative 3D images.
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(a) Raw images and processed images with BSA cluster and vessel segmentation from the
contralateral side. Raw images are in the first column. Yellow spots in the second column represent
segmented BSA clusters. Green surfaces represent segmented blood vessels. (b) Raw images and
processed images with BSA cluster and blood vessel segmentation from the ipsilateral side. Raw
images are in the second column. Size of all 3D images, 450 × 450 × 500 µm. The pressure of FUS
used to treat this sample is 0.2 MPa.
Characterization of the BSA Delivery with the Distance Map
Peaks of all distance maps are located on the negative part of the x-axis,
with a distance of around 1.5 µm to the zero points (Figure3.5). The differences in the peak
locations among different conditions are insignificant. The location of the peak means where
most BSA gathered. BSA uptake by vessels has been observed in untreated brains in the previous
study.(Kucharz et al., 2021) It is acceptable to assume peaks in these distance maps are consistent
with the location of vessels. However, lectin stains vessels on the luminal surface of ECs,
(Robertson et al., 2015) so theoretically, peaks should locate on the positive part of the xaxis. Considering the resolution of lightsheet microscopy, this displacement can be explained by
imaging artifacts.
Based on the previous assumption, clusters on the left of the peak represent a part of those
taken up by vessels (Figure 3.4a iii). Since their locations are closer to the inner surface of vessels,
we define them as inner part clusters. Clusters on the right of the peak of the distance map include
a part of clusters located in vessels but closer to the outer surface of vessels, clusters adhered to
the outer surface of vessels, and clusters delivered out of vessels (Figure 3.4b iii), which we define
as outer part clusters.
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Figure 3.5 Locations of peaks on distance maps of BSA clusters delivered by FUS with the
pressure of 0.4 MPa and 0.2 MPa on the ipsilateral and contralateral sides.
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Figure 3.6 Quantification of outer part BSA clusters delivered by FUS with the pressure of 0.4
MPa and 0.2 MPa on the ipsilateral and contralateral sides. *P<0.05.
Figure 3.6 characterizes the BSA delivery level of different FUS pressure by the amount of
BSA clusters on the right of the peak of the distance map. 0.4 MPa FUS has significant
improvement on the outer part BSA delivery, increasing the mean number of clusters by 6.97-fold
compared with the contralateral side. The fold for 0.2 MPa FUS is 3.58. However, there is no
significant difference between 0.4 MPa and 0.2 MPa shown in this figure.
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Figure 3.7 Quantification of inner part BSA clusters delivered by FUS with the pressure of 0.4
MPa and 0.2 MPa on the ipsilateral and contralateral sides. *P<0.05.
Figure 3.7 characterizes the BSA delivery level of different FUS pressure by the amount of
BSA clusters on the left of the peak of the distance map. 0.4 MPa FUS has significant improvement
on the inner part BSA, increasing the mean number of clusters by 5.58-fold compared with the
contralateral side. The fold for 0.2 MPa FUS is 2.52. However, there is no significant
difference in this characteristic between 0.4 MPa and 0.2 MPa.
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Figure 3.8 The ratio of outer part BSA clusters to all clusters in the brain. *P<0.05.
Figure 3.8 characterizes the BSA delivery level of different FUS pressure by the ratio of
BSA clusters on the right of the peak of the distance map to the total amount. 0.4 MPa FUS shows
significant improvement on the outer part BSA delivery, increasing the mean ratio by 1.13-fold
compared with the contralateral side. However, the fold for 0.2 MPa FUS is 1.10.
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Figure 3.9 The ratio of inner part BSA clusters to all clusters in the brain. *P<0.05.
Figure 3.9 characterizes the BSA delivery level of different FUS pressure by the ratio of
BSA clusters on the left of the peak of the distance map to the total amount. 0.4 MPa FUS
significantly decrease the ratio of clusters by 18.7% compared with the contralateral side, which
implies 0.4 MPa FUS has more improvement on outer part BSA delivery than the inner part. The
decrease ratio for 0.2 MPa FUS is 11.2%.
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Figure 3.10 Quantification of BSA clusters delivered to mouse brains by FUS with the pressure
of 0.4 MPa and 0.2 MPa.
Figure 3.10 characterizes the BSA delivery level of different FUS pressure by the total
amount of BSA clusters in the brain slice. 0.4 MPa FUS has significant improvement on the BSA
delivery, increasing the mean number of clusters by 6.22-fold compared with the contralateral side.
The fold for 0.2 MPa FUS is 3.19. However, it does not show a significant difference in this
characteristic between 0.4 MPa and 0.2 MPa.
Although 0.2 MPa shows a significant difference compared with 0.4 MPa in Figure 3.9 and
Figure 3.10, this difference may come from individual variation among samples rather than
delivery capacity. The ratio of inner part clusters should be the same on the contralateral sides of
0.4 MPa samples and 0.2 MPa samples. However, in Figure 3.9 and Figure 3.10, there is an
obvious difference between samples of two pressures. It is necessary to emphasize that the
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threshold for BSA segmentation is only kept consistent between both sides on one sample, and the
change of the threshold can influence the number and even ratio of inner and outer part
clusters. In consequence, it does not make sense to compare the ipsilateral sides of 0.4 MPa and
0.2 MPa samples directly.
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Chapter 4: Conclusion
Using the image analysis pipeline based on the shortest distance to analyze the 3D
images of cleared brain slices following FUS treatment with different pressure, this study proved
that 0.4 MPa FUS treatment can significantly enhance BSA delivery cross BBB, from both aspects
of the inner part and outer part. whereas 0.2 MPa did not improve the delivery significantly. At the
same time, this study also proved that this research pipeline has the potential to further study
the spatial distribution of drugs delivered by FUS and the bioeffects of FUS treatment.
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Chapter 5: Discussion
Limited by the resolution of light sheet microscopy, only BSA clusters are studied in this
thesis. Single BSA particles diffused out of blood vessels can cause stronger background. However,
it is difficult to quantify BSA single particles by the signal intensity of the background, since the
background in images from light sheet microscopy is also influenced by the transparency of the
ROI and the distance from the light source to the ROI.
BSA clusters far away from blood vessels mostly exist in the brain in the shape of
ellipsoids. There is the possibility that those BSA were taken up by cells. In the future,
immunostaining can be used to observe whether BSA clusters and some kinds of cells are colocalized to validate this assumption.
It's undeniable that this study has some direction that can be improved. Firstly, the number
of replicates is not large enough, which might hide some information in the data. Secondly,
although the wild filed microscope is used to select the ROI before 3D imaging, due to
the different sizes of sample slices, it is difficult to accurately locate the ROI with the light sheet
system after the sample is installed in the chamber. Establishing more rigorous installation
procedures is expected to solve this problem. Besides, in the pilot study, 0.4 MPa FUS was used
and BSA was allowed to cross the BBB for 1 hour. A more obvious contrast is observed on the
ipsilateral side relative to the contralateral side. Reducing this time to 15 minutes has
likely weakened the significance of the result. Last but not least, other experiments should be
designed to quantify the reliability of the analysis pipeline.
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